Kamel Laribi
A5013996935- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Erythropoietin and Anemia Treatment
- Hemoglobinopathies and Related Disorders
- CNS Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Cutaneous lymphoproliferative disorders research
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Iron Metabolism and Disorders
- Platelet Disorders and Treatments
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
- Renal Diseases and Glomerulopathies
- Blood disorders and treatments
- Biosimilars and Bioanalytical Methods
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
Centre Hospitalier du Mans
2016-2025
Le Mans Université
2022
Sorbonne Université
2020
The University of Texas MD Anderson Cancer Center
2019
Centre Hospitalier Universitaire de Caen
2019
Groupe Francophone des Myélodysplasies
2010-2019
Acute Leukemia French Association
2019
Hospices Civils de Lyon
2017
Purpose Magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET-CT) are important techniques in multiple myeloma (MM). We conducted a prospective trial patients with MM aimed at comparing MRI PET-CT respect to the detection of bone lesions diagnosis prognostic value techniques. Patients Methods One hundred thirty-four received combination lenalidomide, bortezomib, dexamethasone (RVD) or without autologous stem-cell transplantation, followed by lenalidomide...
Real-life studies on patients with primary CNS lymphoma (PCNSL) are scarce. Our objective was to analyze, in a nationwide population-based study, the current medical practice management of PCNSL.The French oculo-cerebral network (LOC) database prospectively records all newly diagnosed PCNSL cases from 32 centers. Data between 2011 and 2016 were retrospectively analyzed.We identified 1,002 immunocompetent (43% aged >70 years, median Karnofsky Performance Status [KPS] 60). First-line treatment...
Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible intensive chemotherapy are disappointing. This multicenter, open-label, phase trial randomized (2:1) untreated adults FLT3mut+ AML induction to receive gilteritinib (120 mg/d orally) and azacitidine (GIL + AZA) or (AZA) alone. The primary end point was overall survival (OS). At the interim analysis (August 26, 2020), a total of 123 were treatment...
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone patients newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) considered the best standard of care (SOC). To improve current SOC, we evaluated added value weekly bortezomib (V) to isatuximab plus (IsaRd versus Isa-VRd). This Intergroupe Francophone Myeloma phase 3 study randomized 270 NDMM were TI, aged 65-79 years, IsaRd Isa-VRd arms. The primary endpoint was a minimal residual...
Summary Myeloproliferative neoplasm‐related myelofibrosis is associated with cytopenic or proliferative phases, splenomegaly and constitutional symptoms. Few effective treatments are available small series suggested that interferon could be an option for therapy. We performed a retrospective study of pegylated‐interferon α‐2a (Peg‐ IFN α‐2a) therapy in myelofibrosis. Sixty‐two patients treated Peg‐ at 17 French Belgian centres were included. Responses determined based on the criteria...
MABLE investigated the efficacy and safety of rituximab plus bendamustine or chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received every four weeks for six cycles. Rituximab chlorambucil-treated without a complete response after Cycle 6 monotherapy at least additional cycles until response. The primary endpoint was rate (confirmed by bone marrow biopsy) first-line patients. Secondary endpoints included progression-free survival, overall minimal...
BackgroundThe present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens disease progression in multiple myeloma (MM) patients.Patients MethodsAdult patients initiating any new MM therapy from October 2010 2012 were eligible. A multistage patient/site recruitment model was applied minimize the selection bias; enrollment stratified by country, region, practice type. The patient medical features, history, remission status recorded...
Abstract The purpose of this study is to describe the clinical and prognostic features evaluate outcome different therapeutic approaches among patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who have been diagnosed treated in institutions. A total 398 from 75 centers were included study. Treatment consisted non-Hodgkin lymphoma (NHL)–like regimens 129 (32.8%) acute leukemia (AL)–like 113 (23.5%) patients. In 61 (15.5%) 16 (4.1%) patients, chemotherapy was followed by...
Abstract Myeloproliferative neoplasms (MPNs) are uncommon in children/young adults. Here, we present data on unselected patients diagnosed before 25 years of age included from 38 centers 15 countries. Sequential were included. We identified 444 patients, with median follow-up 9.7 (0-47.8). Forty-nine (11.1%) had a history thrombosis at diagnosis, 49 new thrombotic events recorded (1.16% patient per year [pt/y]), perihepatic vein thromboses most frequent (47.6% venous events), and logistic...
We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed centers affiliated to French Intergroup Myeloproliferative neoplasms. In this study, we report their long-term outcomes correlations mutational patterns driver non-driver mutations analyzed by targeted next generation sequencing. The median age at diagnosis was 66 years old, follow-up since starting interferon 58...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy which was first included as an independent cutaneous lymphoma in the 2008 World Health Organisation (WHO) classification (1). BPDCN usually has extremely poor prognosis, with quick relapses after chemotherapy (2; 3). Here, we report two cases of patients diagnosed 2011 and myelodysplasia, who were treated for time 5-azacytidine (5-Aza); drug approved by Food Drug Administration (FDA) mainly used treatment...
High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safety of guadecitabine high-risk syndrome low blast count acute refractory or relapsing azacitidine. We included 56 with median age 75 years [Interquartile Range (IQR) 69-76]. Fifty-five received at...